Antibiotics-an investment worth making?
Article Abstract:
Demand for new and more effective antibiotics is growing continuously and handsome returns on successful antibiotic drugs make them an interesting option for biotech investment by venture capitalist. However, the dangers from new regulatory, political, scientific and clinical trends are making venture capitalist cautious and they putting serious thought before entering into investments.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Genetech faces the consequences of growth
Article Abstract:
The biotech firm Genetech is unable to produce the pipeline that is necessary to increase its financial growth due to its large size. The failure of recognition as a pharma or even a biotech firm could be avoided by planning strategies for acquisitions and in-licensing.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Asset sales, investment opportunities, and the use of proceeds. Optimal asset location and allocation with taxable and tax-deferred investing
- Abstracts: Investment and financing constraints: evidence from the funding of corporate pension plans. The foundations of freezeout laws in takeovers
- Abstracts: After price complaints, DOD works with Contractors on costs
- Abstracts: Financial factors in R&D budget setting: the impact of interfunctional market coordination, strategic alliances, and the nature of competition
- Abstracts: A passion for collaboration from the get-go: Merk and Co., Inc. and Bioxell show how big pharma and small biotechs can make perfect partners